Fig. 1From: Targeting molecular resistance in castration-resistant prostate cancerAndrogen receptor-dependent mechanisms of resistance in hormone-naïve prostate cancer leading to castration-resistance, and role of current FDA-approved therapies. wtAR, Wild-type androgen receptor; ARV, Androgen receptor variant; mutAR, Mutated androgen receptor; T, Testosterone; DHT, DihydrotestosteroneBack to article page